Quarterly Holdings Report
for
Fidelity Advisor® Equity Growth Fund
February 29, 2024
EPG-NPRT1-0424
1.797923.120
Common Stocks - 97.1% | |||
Shares | Value ($) (000s) | ||
COMMUNICATION SERVICES - 10.0% | |||
Entertainment - 4.9% | |||
Live Nation Entertainment, Inc. (a) | 163,500 | 15,856 | |
Netflix, Inc. (a) | 307,507 | 185,402 | |
Universal Music Group NV | 5,446,884 | 164,444 | |
Warner Music Group Corp. Class A | 2,665,706 | 93,113 | |
458,815 | |||
Interactive Media & Services - 5.1% | |||
Alphabet, Inc. Class A (a) | 2,747,874 | 380,471 | |
Epic Games, Inc. (a)(b)(c) | 3,289 | 2,256 | |
Meta Platforms, Inc. Class A | 199,917 | 97,985 | |
480,712 | |||
TOTAL COMMUNICATION SERVICES | 939,527 | ||
CONSUMER DISCRETIONARY - 11.2% | |||
Automobiles - 0.2% | |||
BYD Co. Ltd. (H Shares) | 999,457 | 24,617 | |
Broadline Retail - 6.5% | |||
Amazon.com, Inc. (a) | 2,679,137 | 473,564 | |
MercadoLibre, Inc. (a) | 52,328 | 83,479 | |
PDD Holdings, Inc. ADR (a) | 306,209 | 38,135 | |
Savers Value Village, Inc. (d) | 664,759 | 13,455 | |
608,633 | |||
Hotels, Restaurants & Leisure - 3.1% | |||
Airbnb, Inc. Class A (a) | 768,493 | 121,015 | |
Booking Holdings, Inc. | 13,180 | 45,719 | |
Domino's Pizza, Inc. | 108,600 | 48,691 | |
Flutter Entertainment PLC (a) | 299,858 | 64,744 | |
Kura Sushi U.S.A., Inc. Class A (a)(d) | 107,348 | 10,201 | |
290,370 | |||
Household Durables - 0.0% | |||
Blu Investments LLC (a)(b)(c) | 12,123,162 | 4 | |
Specialty Retail - 0.4% | |||
TJX Companies, Inc. | 419,799 | 41,619 | |
Textiles, Apparel & Luxury Goods - 1.0% | |||
LVMH Moet Hennessy Louis Vuitton SE | 52,554 | 47,968 | |
Samsonite International SA (a)(e) | 12,616,424 | 44,072 | |
92,040 | |||
TOTAL CONSUMER DISCRETIONARY | 1,057,283 | ||
CONSUMER STAPLES - 1.1% | |||
Beverages - 0.7% | |||
Monster Beverage Corp. | 1,193,002 | 70,506 | |
Personal Care Products - 0.4% | |||
Estee Lauder Companies, Inc. Class A | 228,929 | 34,014 | |
TOTAL CONSUMER STAPLES | 104,520 | ||
ENERGY - 2.4% | |||
Energy Equipment & Services - 0.0% | |||
Schlumberger Ltd. | 90,100 | 4,355 | |
Oil, Gas & Consumable Fuels - 2.4% | |||
Cheniere Energy, Inc. | 487,342 | 75,635 | |
New Fortress Energy, Inc. (d) | 478,455 | 16,818 | |
Range Resources Corp. | 1,234,209 | 39,026 | |
Reliance Industries Ltd. | 2,580,905 | 90,963 | |
222,442 | |||
TOTAL ENERGY | 226,797 | ||
FINANCIALS - 5.9% | |||
Capital Markets - 0.2% | |||
Ares Management Corp. | 141,699 | 18,794 | |
Consumer Finance - 0.2% | |||
Capital One Financial Corp. | 108,700 | 14,958 | |
Financial Services - 4.6% | |||
Apollo Global Management, Inc. | 77,989 | 8,719 | |
Corebridge Financial, Inc. | 773,505 | 19,206 | |
Fiserv, Inc. (a) | 121,428 | 18,126 | |
Global Payments, Inc. | 446,362 | 57,893 | |
MasterCard, Inc. Class A | 336,866 | 159,931 | |
Rocket Companies, Inc. (a)(d) | 1,247,541 | 15,669 | |
Visa, Inc. Class A | 558,500 | 157,854 | |
437,398 | |||
Insurance - 0.9% | |||
Arthur J. Gallagher & Co. | 273,252 | 66,654 | |
BRP Group, Inc. (a) | 686,621 | 19,102 | |
85,756 | |||
TOTAL FINANCIALS | 556,906 | ||
HEALTH CARE - 13.4% | |||
Biotechnology - 3.1% | |||
Adamas Pharmaceuticals, Inc.: | |||
rights (a)(c) | 1,000,100 | 240 | |
rights (a)(c) | 1,000,100 | 90 | |
Alnylam Pharmaceuticals, Inc. (a) | 272,527 | 41,176 | |
Arcellx, Inc. (a) | 61,713 | 4,062 | |
Arrowhead Pharmaceuticals, Inc. (a) | 247,939 | 7,959 | |
Beam Therapeutics, Inc. (a) | 74,295 | 2,934 | |
BioMarin Pharmaceutical, Inc. (a) | 112,947 | 9,745 | |
Blueprint Medicines Corp. (a) | 41,541 | 3,885 | |
Cytokinetics, Inc. (a) | 195,581 | 14,129 | |
Galapagos NV sponsored ADR (a) | 403,761 | 14,176 | |
Gamida Cell Ltd. (a)(d) | 1,892,438 | 681 | |
Gamida Cell Ltd. warrants 4/21/28 (a) | 353,699 | 14 | |
Hookipa Pharma, Inc. (a) | 668,753 | 514 | |
Immunocore Holdings PLC ADR (a) | 169,248 | 11,377 | |
Insmed, Inc. (a) | 637,047 | 17,659 | |
Janux Therapeutics, Inc. (a) | 21,500 | 1,040 | |
Krystal Biotech, Inc. (a) | 33,271 | 5,306 | |
Legend Biotech Corp. ADR (a) | 207,175 | 13,500 | |
Regeneron Pharmaceuticals, Inc. (a) | 92,260 | 89,131 | |
Repligen Corp. (a)(d) | 171,261 | 33,223 | |
Sarepta Therapeutics, Inc. (a) | 56,021 | 7,165 | |
Seres Therapeutics, Inc. (a) | 234,668 | 268 | |
Synlogic, Inc. (a) | 43,125 | 82 | |
Vor Biopharma, Inc. (a) | 474,267 | 1,091 | |
XOMA Corp. (a) | 290,689 | 7,067 | |
286,514 | |||
Health Care Equipment & Supplies - 3.7% | |||
Align Technology, Inc. (a) | 48,300 | 14,607 | |
Boston Scientific Corp. (a) | 3,240,634 | 214,562 | |
Glaukos Corp. (a) | 200,502 | 17,762 | |
Hologic, Inc. (a) | 199,200 | 14,701 | |
Inspire Medical Systems, Inc. (a) | 64,309 | 11,514 | |
Lantheus Holdings, Inc. (a) | 93,767 | 6,130 | |
Masimo Corp. (a) | 434,327 | 55,828 | |
Penumbra, Inc. (a) | 48,771 | 11,457 | |
Pulmonx Corp. (a) | 196,800 | 1,814 | |
RxSight, Inc. (a) | 53,800 | 2,936 | |
351,311 | |||
Health Care Providers & Services - 0.9% | |||
HealthEquity, Inc. (a) | 1,042,156 | 86,093 | |
Health Care Technology - 0.1% | |||
Evolent Health, Inc. Class A (a) | 304,700 | 10,332 | |
Life Sciences Tools & Services - 2.9% | |||
Agilent Technologies, Inc. | 116,835 | 16,048 | |
Bio-Techne Corp. | 240,195 | 17,671 | |
Bruker Corp. | 488,616 | 42,285 | |
Chemometec A/S | 120,373 | 8,556 | |
Codexis, Inc. (a) | 1,123,114 | 5,222 | |
Danaher Corp. | 301,812 | 76,401 | |
MaxCyte, Inc. (a) | 1,127,055 | 5,184 | |
Sartorius Stedim Biotech | 119,019 | 32,712 | |
Thermo Fisher Scientific, Inc. | 115,114 | 65,636 | |
269,715 | |||
Pharmaceuticals - 2.7% | |||
Aclaris Therapeutics, Inc. (a) | 156,678 | 186 | |
Chugai Pharmaceutical Co. Ltd. | 417,134 | 16,694 | |
Eli Lilly & Co. | 312,426 | 235,469 | |
Teva Pharmaceutical Industries Ltd. sponsored ADR (a) | 45,900 | 604 | |
252,953 | |||
TOTAL HEALTH CARE | 1,256,918 | ||
INDUSTRIALS - 14.3% | |||
Electrical Equipment - 1.6% | |||
Eaton Corp. PLC | 410,085 | 118,515 | |
HD Hyundai Electric Co. Ltd. | 99,470 | 9,266 | |
Nextracker, Inc. Class A | 364,913 | 20,523 | |
148,304 | |||
Ground Transportation - 4.9% | |||
Uber Technologies, Inc. (a) | 5,842,769 | 464,500 | |
Industrial Conglomerates - 1.6% | |||
General Electric Co. | 968,600 | 151,964 | |
Machinery - 2.1% | |||
Energy Recovery, Inc. (a) | 287,293 | 4,490 | |
Ingersoll Rand, Inc. | 1,118,995 | 102,198 | |
Parker Hannifin Corp. | 118,763 | 63,592 | |
Westinghouse Air Brake Tech Co. | 183,497 | 25,926 | |
196,206 | |||
Passenger Airlines - 0.5% | |||
Ryanair Holdings PLC sponsored ADR | 354,086 | 48,952 | |
Professional Services - 2.7% | |||
Equifax, Inc. | 486,013 | 132,968 | |
KBR, Inc. | 1,282,425 | 76,984 | |
RELX PLC sponsored ADR | 107,200 | 4,708 | |
TransUnion | 445,791 | 34,607 | |
249,267 | |||
Trading Companies & Distributors - 0.9% | |||
Ferguson PLC | 405,403 | 84,360 | |
TOTAL INDUSTRIALS | 1,343,553 | ||
INFORMATION TECHNOLOGY - 38.7% | |||
Electronic Equipment, Instruments & Components - 1.2% | |||
Flex Ltd. (a) | 2,040,781 | 57,448 | |
Jabil, Inc. | 416,362 | 59,994 | |
117,442 | |||
IT Services - 1.6% | |||
Gartner, Inc. (a) | 77,439 | 36,053 | |
MongoDB, Inc. Class A (a) | 262,707 | 117,582 | |
153,635 | |||
Semiconductors & Semiconductor Equipment - 16.3% | |||
Aixtron AG | 640,081 | 17,765 | |
Allegro MicroSystems LLC (a) | 1,208,469 | 38,055 | |
ASML Holding NV (depository receipt) | 135,187 | 128,655 | |
BE Semiconductor Industries NV | 447,902 | 80,916 | |
eMemory Technology, Inc. | 36,000 | 3,082 | |
KLA Corp. | 89,805 | 61,274 | |
Marvell Technology, Inc. | 258,234 | 18,505 | |
Micron Technology, Inc. | 481,100 | 43,592 | |
Monolithic Power Systems, Inc. | 45,165 | 32,521 | |
NVIDIA Corp. | 1,020,642 | 807,450 | |
NXP Semiconductors NV | 300,039 | 74,929 | |
SiTime Corp. (a) | 313,869 | 29,033 | |
Taiwan Semiconductor Manufacturing Co. Ltd. sponsored ADR | 1,203,409 | 154,843 | |
Universal Display Corp. | 262,951 | 45,864 | |
1,536,484 | |||
Software - 16.0% | |||
ASAPP, Inc. warrants 8/28/28 (a)(b)(c) | 2,071,818 | 4,869 | |
HubSpot, Inc. (a) | 104,506 | 64,669 | |
Manhattan Associates, Inc. (a) | 249,639 | 63,241 | |
Microsoft Corp. | 3,049,881 | 1,261,552 | |
Monday.com Ltd. (a)(d) | 103,753 | 23,138 | |
NICE Ltd. sponsored ADR (a) | 185,350 | 45,439 | |
ServiceNow, Inc. (a) | 44,949 | 34,671 | |
Volue A/S (a) | 1,205,893 | 2,946 | |
1,500,525 | |||
Technology Hardware, Storage & Peripherals - 3.6% | |||
Apple, Inc. | 1,860,219 | 336,235 | |
TOTAL INFORMATION TECHNOLOGY | 3,644,321 | ||
MATERIALS - 0.1% | |||
Chemicals - 0.1% | |||
Aspen Aerogels, Inc. (a)(d) | 510,078 | 8,763 | |
TOTAL COMMON STOCKS (Cost $5,301,669) | 9,138,588 | ||
Convertible Preferred Stocks - 0.2% | |||
Shares | Value ($) (000s) | ||
CONSUMER DISCRETIONARY - 0.0% | |||
Textiles, Apparel & Luxury Goods - 0.0% | |||
Canva, Inc.: | |||
Series A (b)(c) | 846 | 902 | |
Series A2 (b)(c) | 154 | 164 | |
1,066 | |||
FINANCIALS - 0.0% | |||
Financial Services - 0.0% | |||
Akeana Series C (b)(c) | 57,400 | 730 | |
HEALTH CARE - 0.0% | |||
Biotechnology - 0.0% | |||
ElevateBio LLC Series C (a)(b)(c) | 111,100 | 386 | |
INFORMATION TECHNOLOGY - 0.1% | |||
Software - 0.1% | |||
ASAPP, Inc.: | |||
Series C (a)(b)(c) | 367,427 | 1,066 | |
Series D (b)(c) | 3,611,038 | 10,183 | |
11,249 | |||
MATERIALS - 0.1% | |||
Metals & Mining - 0.1% | |||
Illuminated Holdings, Inc.: | |||
Series C2 (a)(b)(c) | 76,285 | 1,375 | |
Series C3 (a)(b)(c) | 95,356 | 1,719 | |
Series C4 (a)(b)(c) | 27,230 | 491 | |
Series C5 (a)(b)(c) | 53,844 | 971 | |
4,556 | |||
TOTAL CONVERTIBLE PREFERRED STOCKS (Cost $26,706) | 17,987 | ||
Convertible Bonds - 0.0% | |||
Principal Amount (f) (000s) | Value ($) (000s) | ||
MATERIALS - 0.0% | |||
Metals & Mining - 0.0% | |||
Illuminated Holdings, Inc. 0% (b)(c)(g) (Cost $1,619) | 1,619 | 1,654 | |
Preferred Securities - 0.0% | |||
Principal Amount (f) (000s) | Value ($) (000s) | ||
MATERIALS - 0.0% | |||
Metals & Mining - 0.0% | |||
Illuminated Holdings, Inc. 0% (b)(c)(g) (Cost $2,252) | 2,252 | 2,297 | |
Money Market Funds - 3.3% | |||
Shares | Value ($) (000s) | ||
Fidelity Cash Central Fund 5.39% (h) | 257,645,106 | 257,697 | |
Fidelity Securities Lending Cash Central Fund 5.39% (h)(i) | 48,797,804 | 48,803 | |
TOTAL MONEY MARKET FUNDS (Cost $306,500) | 306,500 | ||
TOTAL INVESTMENT IN SECURITIES - 100.6% (Cost $5,638,746) | 9,467,026 |
NET OTHER ASSETS (LIABILITIES) - (0.6)% | (58,440) |
NET ASSETS - 100.0% | 9,408,586 |
Any values shown as $0 in the Schedule of Investments may reflect amounts less than $500.
Legend
(a) | Non-income producing |
(b) | Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $29,067,000 or 0.3% of net assets. |
(c) | Level 3 security |
(d) | Security or a portion of the security is on loan at period end. |
(e) | Security exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At the end of the period, the value of these securities amounted to $44,072,000 or 0.5% of net assets. |
(f) | Amount is stated in United States dollars unless otherwise noted. |
(g) | Security is perpetual in nature with no stated maturity date. |
(h) | Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request. |
(i) | Investment made with cash collateral received from securities on loan. |
Additional information on each restricted holding is as follows: | ||
Security | Acquisition Date | Acquisition Cost ($) (000s) |
Akeana Series C | 1/23/24 | 732 |
ASAPP, Inc. warrants 8/28/28 | 8/29/23 | 0 |
ASAPP, Inc. Series C | 4/30/21 | 2,424 |
ASAPP, Inc. Series D | 8/29/23 | 13,944 |
Blu Investments LLC | 5/21/20 | 21 |
Canva, Inc. Series A | 9/22/23 | 902 |
Canva, Inc. Series A2 | 9/22/23 | 164 |
ElevateBio LLC Series C | 3/09/21 | 466 |
Epic Games, Inc. | 3/29/21 | 2,911 |
Illuminated Holdings, Inc. Series C2 | 7/07/20 | 1,907 |
Illuminated Holdings, Inc. Series C3 | 7/07/20 | 2,861 |
Illuminated Holdings, Inc. Series C4 | 1/08/21 | 980 |
Illuminated Holdings, Inc. Series C5 | 6/16/21 | 2,326 |
Illuminated Holdings, Inc. 0% | 6/14/23 | 1,619 |
Illuminated Holdings, Inc. 0% | 9/27/23 | 2,252 |
Affiliated Central Funds
Fiscal year to date information regarding the Fund's investments in Fidelity Central Funds, including the ownership percentage, is presented below.
Affiliate (Amounts in thousands) | Value, beginning of period ($) | Purchases ($) | Sales Proceeds ($) | Dividend Income ($) | Realized Gain (loss) ($) | Change in Unrealized appreciation (depreciation) ($) | Value, end of period ($) | % ownership, end of period |
Fidelity Cash Central Fund 5.39% | 91,729 | 433,997 | 268,029 | 2,443 | - | - | 257,697 | 0.5% |
Fidelity Securities Lending Cash Central Fund 5.39% | 54,549 | 95,574 | 101,320 | 43 | - | - | 48,803 | 0.2% |
Total | 146,278 | 529,571 | 369,349 | 2,486 | - | - | 306,500 | |
Amounts in the dividend income column in the above table include any capital gain distributions from underlying funds.
Amounts in the dividend income column for Fidelity Securities Lending Cash Central Fund represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium payments received for lending certain types of securities.
Investment Valuation
Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Securities transactions are accounted for as of trade date. The Board of Trustees (the Board) has designated the Fund's investment adviser as the valuation designee responsible for the fair valuation function and performing fair value determinations as needed. The investment adviser has established a Fair Value Committee (the Committee) to carry out the day-to-day fair valuation responsibilities and has adopted policies and procedures to govern the fair valuation process and the activities of the Committee. In accordance with these fair valuation policies and procedures, which have been approved by the Board, the Fund attempts to obtain prices from one or more third party pricing services or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with the policies and procedures. Factors used in determining fair value vary by investment type and may include market or investment specific events, transaction data, estimated cash flows, and market observations of comparable investments. The frequency that the fair valuation procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee manages the Fund's fair valuation practices and maintains the fair valuation policies and procedures. The Fund's investment adviser reports to the Board information regarding the fair valuation process and related material matters.
The inputs to valuation techniques used to value investments are categorized into a disclosure hierarchy consisting of three levels as shown below:
Level 1 - Unadjusted quoted prices in active markets for identical investments
Level 2 - other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)
Level 3 - unobservable inputs (including the Fund's own assumptions based on the best information available)
Valuation techniques used to value investments by major category are as follows:
Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For any foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.
Debt securities, including restricted securities, are valued based on evaluated prices received from third party pricing services or from brokers who make markets in such securities. Convertible Bonds and Preferred Securities are valued by pricing services who utilize matrix pricing which considers yield or price of bonds of comparable quality, coupon, maturity and type or by broker-supplied prices. When independent prices are unavailable or unreliable, debt securities may be valued utilizing pricing methodologies which consider similar factors that would be used by third party pricing services. Debt securities are generally categorized as Level 2 in the hierarchy but may be Level 3 depending on the circumstances.
Investments in any open-end mutual funds are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy.
Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.
For additional information on the Fund's significant accounting policies, please refer to the Fund's most recent semiannual or annual shareholder report.
The fund's schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund's shareholders. For more information regarding the fund and its holdings, please see the fund's most recent prospectus and annual report.
Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.